Title:
AI for drug design – development and testing of ai methods and molecule parameterization
Agreement Value:
$156,750.00
Agreement Date:
Mar 25, 2020 - Mar 24, 2023
Description:
Designing a drug for a specific disease type is highly challenging due to tremendous molecular search space and limited understanding about the disease of interest. Successful discovery of a medicine for a target (gene/protein/pathway) usually last for many years and costs a private pharmaceutical organization billions of dollars, which in turn determines the unaffordable price of medicines in the Canadian and global markets. The emerging of massive biochemical and high-throughput genomic data acquisition techniques and the rise of advanced artificial intelligence paradigms provide an unprecedented opportunity for automatic design of new drugs with much faster pace and much lower cost, igniting hopes to discovery drugs for diseases where no medicines have been found yet. A develop a data- and AI-driven drug design platform/pipeline will be developed for precise and effective treatment of cancers and complex diseases. The project will take advantage of NRC’s unique multidisciplinary expertise in AI, data science, and human health therapeutics, as well as external collaborators’ knowledge and facilities, to tackle challenges in every step of drug design. Project technologies and outcomes will be disruptive and beneficial to all Canadians.
This project will focus on the development and testing of AI methods and molecule parameterization.
Organization:
National Research Council Canada
Expected Results:
In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators. In the long term, find collaborative solutions to public policy challenges and create stronger innovation systems.
Location:
St. Catharines, Ontario, CA L2S 3A1
Reference Number:
172-2021-2022-Q3-947434
Report Type:
Grants and Contributions
Recipient Business Number:
118819531
Additional Information:
This agreement has been amended 1 time(s). The total amended value is 156,750 dollars and the end date of this agreements has been modified by 358 days.
Amendment Date
Dec 7, 2021
Recipient's Legal Name:
Brock University
Federal Riding Name:
Niagara Centre
Federal Riding Number:
35066
Program:
Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives
Program Purpose:
Collaborate on multiparty research and development programs to catalyze transformative, high-risk, high-reward research with the potential for game-changing scientific discoveries and technological breakthroughs in priority areas.